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Aim: The effect of conservative versus liberal oxygen therapy on mortality 
rates in post cardiac arrest patients is uncertain.  
Methods: We undertook an individual patient data meta-analysis of patients 
randomised in clinical trials to conservative or liberal oxygen therapy after a 
cardiac arrest.  The primary end point was mortality at last follow-up. 
Results: Individual level patient data were obtained from seven randomised 
clinical trials with a total of 429 trial participants included.  Four trials enrolled 
patients in the pre-hospital period.  Of these, two provided protocol-directed 
oxygen therapy for 60 minutes, one provided it until the patient was handed 
over to the emergency department staff, and one provided it for a total of 72 
hours or until the patient was extubated.  Three trials enrolled patients after 
intensive care unit (ICU) admission and generally continued protocolised 
oxygen therapy for a longer period, often until ICU discharge.  A total of 90 of 
221 patients (40.7%) assigned to conservative oxygen therapy and 103 of 206 
patients (50%) assigned to liberal oxygen therapy had died by this last point of 
follow-up; absolute difference; odds ratio (OR) adjusted for study only; 0.67; 
95% CI 0.45 to 0.99; P=0.045; adjusted OR, 0.58; 95% CI 0.35 to 0.96; 
P=0.04. 
Conclusion: Conservative oxygen therapy was associated with a statistically 
significant reduction in mortality at last follow-up compared to liberal oxygen 
therapy but the certainty of available evidence was low or very low due to 
bias, imprecision, and indirectness. 










Withdrawal of life sustaining treatment based on prognostication of a poor 
neurological outcome following hypoxic ischaemic brain injury is a common 
cause of death among post cardiac arrest patients on the Intensive Care Unit 
(ICU)[1]. It is biologically plausible that the liberal use of oxygen that occurs 
with standard management of comatose post cardiac arrest patients 
contributes to secondary brain injury[2]. In particular, exposure to 
hyperoxaemia worsens brain damage in animal models of hypoxic ischaemic 
encephalopathy[3].  Hyperoxaemia is independently associated with 
increased mortality risk in some observational studies of post cardiac arrest 
patients[4-7].  However, this association has not been shown in all studies[8, 
9] and conservative use of oxygen may increase hypoxaemia, which is 
consistently associated with increased mortality risk[4-9].  Thus, clinicians are 
uncertain about the optimal oxygen target in these patients. 
 
Several randomised controlled trials have compared conservative with liberal 
oxygen therapy in patients resuscitated from cardiac arrest[10-14].  Some 
other trials have compared such oxygen therapy regimens in heterogeneous 
ICU patient populations[15-17] and these trials include patients with possible 
hypoxic ischaemic encephalopathy.  However, no individual patient level data 
meta-analysis that includes all patients with possible hypoxic ischaemic 
encephalopathy from randomised controlled trials of conservative vs. liberal 










We performed a systematic review, aggregate data meta-analysis and 
individual level patient data meta-analysis using data from patients post 
cardiac arrest with possible hypoxic ischaemic encephalopathy from 
randomised controlled trials that compared liberal versus conservative oxygen 
regimens.  Our primary hypothesis was that conservative oxygen therapy 
would reduce all-cause mortality at the last point of follow-up.  Our secondary 
hypothesis was that conservative oxygen therapy would increase the 




Study design, trial and patient-level eligibility criteria 
We performed a systematic review, aggregate data meta-analysis and 
individual patient data meta-analysis of randomised controlled trials.  We 
searched the Cochrane Central Register of Controlled Trials, MEDLINE, and 
EMBASE from inception to August 11 2020, without language restrictions, for 
randomised controlled trials comparing the use of liberal and conservation 
oxygen therapies in adults with suspected hypoxic ischaemic encephalopathy. 
The specific search strategies used are shown in the eMethods in the 
Electronic Supplemental Material (ESM).  Randomised controlled trials that 
included heterogeneous populations of patients who were mechanically 
ventilated in ICU were included provided that individuals who fulfilled our 
patient level eligibility criteria could be identified using baseline characteristics 











We included adults (aged at least 18 years of age) with possible hypoxic 
ischaemic encephalopathy, defined as: (i) mechanically ventilated in ICU with 
an ICU admission diagnosis of cardiac arrest, OR (ii) a clinical ICU admission 
diagnosis of confirmed or suspected hypoxic ischaemic encephalopathy, OR 
(iii) unconscious (GCS<9) with an endotracheal tube or supraglottic airway in 
situ with sustained return of spontaneous circulation (ROSC) following a 
cardiac arrest.  We excluded patients who were pregnant. 
 
This trial was prospectively registered (PROSPERO registration number: 
CRD42019138931).  All trials included in this analysis received ethics 
approval and additional approvals to allow for data sharing were obtained 
where required. 
 
Data extraction plan 
Titles and/or abstracts of studies were retrieved using the search strategy and 
those from additional sources were screened independently by two review 
authors to identify studies that potentially meet the inclusion criteria outlined 
above. The full text of potentially eligible studies were retrieved and 
independently assessed for eligibility by two review team members. Any 
disagreement between them over the eligibility of a particular study was 
resolved through discussion with a third reviewer. 
 
Risk of bias (quality assessment) 
Data supplied for included randomised controlled trials were checked for: 









patient characteristics at randomisation, pattern of randomisation); follow-up 
and censoring pattern. Summary tables were checked with the trial protocol 
and latest trial report or publication. Any discrepancies or unusual patterns 
were checked with the study investigator.  
 
Outcome variables 
The main outcomes were pre-specified in advance and were as follows: (i) 
mortality at last reported time point (primary end point); (ii) "good" functional 
outcome defined at last reported time point based on either: a cerebral 
performance category (CPC) score of 1 or 2, OR a Glasgow Outcome Scale - 
Extended (GOS-E) score of 5 or more; (iii) survival time; (iv) in-hospital 
mortality; (v) 30 day mortality; (vi) 90 day mortality; and, (v) 180 day mortality. 
 
Definitions of intervention and control groups 
The treatment arm with the lower oxygen target, measured by any one of the 
following: fraction of inspired oxygen (FIO₂), arterial partial pressure of oxygen 
(PaO₂), arterial oxygen saturation (measured by blood analysis), or peripheral 
oxygen saturation (measured by a pulse oximeter [SpO₂]) was defined as the 
conservative arm (intervention).   
 
The treatment arm with the higher oxygen target, measured by any one of the 
following: fraction of inspired oxygen (FIO₂), arterial partial pressure of oxygen 
(PaO₂), arterial oxygen saturation (measured by blood analysis), or peripheral 
oxygen saturation (measured by a pulse oximeter [SpO₂]) was defined as the 











Baseline variables of interest, effect modifiers, and confounders 
Investigators for the included studies supplied line by line individual participant 
data comprising: (i) de-identified patient study number; (ii) treatment group 
assignment; (iii) baseline characteristics: age; gender; arrest location; 
bystander response; first monitored rhythm; cause of arrest; presence of ST-
elevation myocardial infarction (STEMI); time to response; time to 
defibrillation; time to sustained ROSC; comorbidities; drugs given during 
resuscitation; pre-randomisation mean arterial pressure; pre-randomisation 
arterial partial pressure of carbon dioxide (PaCO2); (iv) co-interventions: use 
of targeted temperature management; neuroprognostication tests; (v) 
oxygenation data: all oxygenation data available from all studies; (vi) outcome 
data: mortality at last reported time point; survival time from randomisation; in-
hospital & day 180 mortality; cause-specific mortality (neurological cause of 
death vs. non-neurological cause of death); neurological outcome at six 
months following randomisation (based on CPC and/or GOS-E). 
 
Subgroups 
Pre-specified subgroup pairs of interest were as follows: (i) patients with in-
hospital arrest versus out of hospital arrest; (ii) patients with a medical cause 
of cardiac arrest versus a non-medical cause of cardiac arrest. 
 
Statistical analysis plan 
Aggregate data were initially used for an analysis of all-cause mortality at last 










from which estimates of risks of death were derived.  Data were pooled using 
the Mantel-Haenszel weighting method and presented as relative risk (RR) 
and 95% confidence intervals (CI).  All further analyses were conducted using 
individual level patient data from all randomised participants.  Baseline 
com a i on  b  ea men  g o  e e e fo med ing a 2 test for 
o o ion  o  a Fi he  E ac  e  he e n mbe  e e mall, S den  T-
test for normally distributed data and Wilcoxon Rank sum test otherwise with 
results reported as numbers (%), mean SD, or median [IQR] respectively. 
 
Outcomes were analysed on an intention to treat basis with no imputation 
unless specified.  Mortality and the proportion of patients with a good 
neurological outcome by treatment group were compared using logistic 
regression adjusting for study as a fixed effect.  The numbers at risk in each 
group and the number and proportion of events were reported as well as the 
equivalent absolute risk difference and relative risk along with corresponding 
95% confidence intervals (95% CI).  The proportion of patients with a good 
neurological outcome by treatment group were analysed and reported in a 
similar fashion.   
 
Survival times were compared using Cox-proportional hazards regression 
adjusted for study as a fixed effect.  Results were presented using Kaplan 
Meier curves with group comparison using a log-rank test.  We undertook 
sensitivity analyses adjusting for pre-specified covariates that predict outcome 
in cardiac arrest patients (age, whether or not the cardiac arrest was 









shockable rhythm, the time until sustained return of circulation).  We 
conducted an additional sensitivity accounting for an observed baseline 
imbalance in the proportions of patients by treatment group who had a 
previous myocardial infarction and who had a cardiac arrest with a medical 
cause.  In addition, for survival we conducted a sensitivity analysis in which all 
hospital survivors from the EXACT pilot trial were assigned a survival time of 
30 days. This assumption was made because survival times for hospital 
survivors were not available and was based on the findings from 
PARAMEDIC-2 where hospital mortality in a similar population was found to 
closely mirror 30 day mortality[18].  In all analyses a two-sided P value of 0.05 
was used to indicate statistical significance.  P values for secondary end 
points and subgroup analyses were not adjusted for multiplicity and should be 
considered hypothesis-generating. 
 
All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, 
NC) and Review Manager (RevMan) Version 5.4. (The Cochrane 





Individual level patient data were obtained from seven out of eight randomised 
controlled trials identified in our systematic review with a total of 429 trial 
participants included.  Details of the included trials and of the trial from which 












Of the 429 trial participants included in this analysis, 222 were assigned to 
conservative oxygen therapy and 207 were assigned to liberal oxygen therapy 
(Figure 1).  Compared with patients assigned to liberal oxygen therapy, those 
assigned to conservative oxygen therapy were more likely to have an initial 
rhythm that was shockable, more likely to have medical cause of cardiac 
arrest, and less likely to have had a prior myocardial infarction (Table 1).  In 
other respects, the study groups had similar baseline characteristics (Table 1 
and Table S2, ESM).   
 
Oxygen therapy  
Four trials enrolled patients in the pre-hospital period (Table 2).  Of these, two 
provided protocol-directed oxygen therapy for 60 minutes, one provided it until 
the patient was handed over to the emergency department staff, and one 
provided it for a total of 72 hours or until the patient was extubated.  Three 
trials enrolled patients following ICU admission.  The duration of protocol-
directed oxygen therapy was generally longer in these trials than in the trials 
that commenced study treatment in the pre-hospital period with the largest 
providing protocol-directed oxygen therapy for up to 28 days. 
 
Co-interventions 
Data on co-interventions and neuroprognostic testing were not available for all 
participants because they were not collected in all trials (Table S3, ESM).  
However, for those participants where data were available, there were no 










during resuscitation.  Targeted temperature management was used in over 
90% of patients in both groups.  Data on neuroprognostic tests undertaken 
were only available for one study[19], but for this study, use of such testing 
was similar by treatment group. 
 
Patient outcomes 
The duration of follow-up varied by study ranging from follow-up to hospital 
discharge to follow-up to 365 days (Table S1, ESM).  A total of 90 of 221 
patients (40.7%) assigned to conservative oxygen therapy and 103 of 206 
patients (50%) assigned to liberal oxygen therapy had died by this last point of 
follow-up; odds ratio (OR) (adjusted for study only); 0.67; 95% CI 0.45 to 0.99; 
P=0.045; OR (adjusted for study and pre-specified baseline variables), 0.58; 
95% CI 0.35 to 0.96; P=0.04 (Table 3 and Figure 2).  Findings were similar in 
a sensitivity analysis incorporating adjustment for observed baseline 
imbalances between treatment groups including whether the patient had 
previously had an acute myocardial infarction and whether the cardiac arrest 
was of presumed to have a medical cause (Table S4, ESM).  Findings in the 
aggregate data meta-analysis were similar to those of the individual patient 
data meta-analysis (Figure 3). 
 
Secondary outcomes  
In-hospital, 30-day, 90-day, and 180-day mortality were consistently lower in 
patients assigned to conservative oxygen therapy (Table 3).  Among patients 
from trials where neurological outcomes were formally assessed at six 










and 66 of 145 (45.5%) assigned to liberal oxygen therapy had a favourable 
neurological outcome at six months; OR 1.53; 95% CI 0.96 to 2.46; P=0.08; 
adjusted OR 1.62; 95% CI 0.95 to 2.76; P=0.07.   Findings in relation to all 
secondary outcome variables were similar in sensitivity analyses incorporating 
adjustment for observed baseline imbalances between treatment groups in 
whether the patient had previously had an acute myocardial infarction and 
whether the cardiac arrest was of presumed to have a medical cause (Table 
S4, ESM).  Survival analyses using imputation for duration of survival among 




A total of 406 patients had an OHCA and 23 had an IHCA.  All but 11 patients 
had a cardiac arrest of presumed medical cause.  There were no statistically 
significant interactions between treatment group allocation and the various 
study outcomes for patients by location of arrest (Table S5, ESM).  Because 
of small numbers, interaction analyses were not performed based on whether 
or not cardiac arrest was of a presumed primary medical cause.  Findings 
limited to patients with a presumed primary medical cause of arrest, which 




In this individual patient data meta-analysis of randomised controlled trials 
comparing conservative with liberal oxygen therapy in patients with possible 









significantly reduced mortality at the last follow-up.  These findings were 
robust to adjustment for pre-specified baseline covariates and in other 
sensitivity analyses.   
 
Our primary outcome variable findings are consistent with animal data[3] and 
some observational data[4-7, 9] and support the hypothesis that conservative 
oxygen therapy reduces mortality in cardiac arrest patients.  The findings of 
our aggregate data meta-analysis and individual data meta-analysis are 
concordant but the latter analysis offers the considerable advantage of 
allowing adjustment for important patient-level baseline variables that are 
powerful predictors of outcome in cardiac arrest patients[20].  There was no 
evidence of heterogeneity in findings of trials included.   Our study 
synthesises individual patient-level data from all trials identified by systematic 
review with the exception of ten patients admitted to ICU following a cardiac 
arrest in the Oxygen-ICU trial[17].  Because we used mortality at last known 
point of contact as our primary outcome variable, most trial participants were 
included in our primary analysis.   
 
Despite the strengths of our analysis, based on the GRADE (Grading of 
Recommendations, Assessment, Development and Evaluations) 
approach[21], we consider that the certainty of evidence supporting 
conservative oxygen therapy following cardiac arrest is low or very low for a 
number of reasons.  First, some data for secondary outcomes were not 
available for some patients and the between-group differences in favourable 










significant.  Secondly, oxygen therapy is, by necessity, an open label therapy 
and we cannot exclude the possibility that patients assigned to conservative 
oxygen therapy were treated differently from patients assigned to liberal 
oxygen therapy.  Although mortality has a low risk of ascertainment bias, 
decisions related to withdrawal of life sustaining therapies could have been 
influenced by knowledge of treatment assignment and no trials protocolised 
decision-making in relation to withdrawal of life-sustaining therapies[22].  
Thirdly, the 95% confidence intervals around effect size estimates are 
imprecise and even one additional death in the conservative oxygen therapy 
group in any trial would mean that the primary end point findings were not 
statistically significant.  Fourthly, the included trials evaluated oxygen 
regimens in a mixture of pre-hospital and ICU settings.  Moreover, oxygen 
regimens varied in duration from one hour to 28 days or more, and the 
amount of oxygen delivered in the regimens tested varied.  Thus, we consider 
that the strength of our findings should be downgraded because of 
indirectness.  Finally, further data are needed on the effect of different oxygen 
regimens on neurological outcomes, in particular.  Such data were available 
for fewer than 70% of patients included in this analysis. 
 
CONCLUSIONS 
In this individual patient data meta-analysis of randomised controlled trials 
conservative oxygen therapy was associated with reduced mortality at last 
follow-up compared with liberal oxygen therapy.  However, based on the risk 
of bias, imprecision of effect size estimates, and indirectness of evidence for 










available evidence supporting the use of conservative oxygen therapy in 
cardiac arrest patients is low or very low.  
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Figure 1.  Participant flow diagram  









 Figure 1.  Participant flow diagram  
 









Figure 2.  Kaplan-Meier survival estimates of the probably of survival* 
* The EXACT pilot trial was excluded from this analysis because duration of 
survival data were not recorded.  The hazard ratio adjusted for study was 0.72 
(95%CI, 0.52 to 0.97), P=0.03.  The hazard ratio adjusted for age, whether or 
not the cardiac arrest was witnessed, whether or not there was bystander 
CPR, whether there was a shockable rhythm, the time until sustained return of 
circulation; whether the patient had previously had an acute myocardial 
infarction, and whether there was a cardiac arrest of presumed cardiac cause, 
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Figure 3.  Aggregate data meta-analysis findings for the effect of liberal 
oxygen vs conservative oxygen on mortality at last follow-up* 
* The CLOSE-I trial was not included in the aggregate data meta-analysis 
because all four patients in the CLOSE-I trial who had a cardiac arrest prior to 
randomisation we allocated to liberal oxygen. 
 
 
Table 1: Baseline characteristics* 
 
Characteristic Conservative oxygen (n=222) 
Liberal oxygen  
(n=207) 
Age  yr 63.0±14.3 61.1±14.9 
Male sex  no. (%) 178 (80.2%) 163 (78.7%) 
Arrest location in-hospital  no. (%) 10 (4.5%) 13 (6.3%) 
Emergency department 3 (1.4%) 6 (2.9%) 
Hospital w ard 5 (2.3%) 3 (1.4%) 
ICU 1 (0.5%) 0 (0%) 
Operating theatre 0 (0%) 1 (0.5%) 
Other location in hospital 1 (0.5%) 3 (1.4%) 
Arrest location Out-of-hospital   
Home / residence 72 (32.4%) 67 (32.4%) 
Assisted living / nursing home 1 (0.5%) 2 (1.0%) 
Other location (not in hospital) 80 (36.0%) 70 (33.8%) 
Arrest location data missing 59 (26.6%) 55 (26.6%) 




 Figure 3.  Aggregate data meta-analysis findings for the effect of 
liberal oxygen vs conservative oxygen on mortality at last follow-up* 
 
 
* The CLOSE-I trial was not included in the aggregate data meta-analysis because all four patients in the 











Received bystander CPR  no. (%) 172 (77.5%) 155 (74.9%) 
First monitored rhythm  no. (%)   
AED shockable / VF / pulseless VT* 184 (82.9%) 154 (74.4%) 
Pulseless electrical activity 20 (9.0%) 21 (10.1%) 
Asystole 9 (4.1%) 12 (5.8%) 
Bradycardia  0 (0%) 3 (1.4%) 
AED non-shockable  2 (0.9%) 1 (0.5%) 
No cardiac arrest 2 (0.9%) 1 (0.5%) 
First monitored rhythm data missing* 5 (2.3%) 14 (6.8%) 
Cause of arrest  no. (%)   
Medical* 205 (92.3%) 177 (85.5%) 
Asphyxia 3 (1.4%) 4 (1.9%) 
Drug overdose 0 (0%) 2 (1.0%) 
Drow ning 0 (0%) 1 (0.5%) 
Trauma 0 (0%) 1 (0.5%) 
Cause of arrest data missing 14 (6.3%) 22 (10.6%) 
Previous AMI* 18/148 (12.2%) 29/138 (21.0%) 
Response times - minutes   
Time to EMS or resuscitation team response 7.3±5.1; n=172 6.6±4.6; n=171 
Time to defibrillation, median [IQR] 6.5 [4-11]; n=82 6 [1-9]; n=81 
Time to ROSC 14.7±10.5; n=172 15.2±12; n=171 
Plus-minus values will be expressed as mean ± SD.   
* Statistically significant differences in baseline characteristics between groups are indicated by * for P < 0.05. 
Data on whether or not the arrest was witnessed and whether bystander CPR was performed were missing for four 
patients allocated to liberal oxygen therapy. 
Abbreviations: AED: Automated External Defibrillator; CPR: cardiopulmonary resuscitation; EMS: Emergency Medical 
Services; ICU: Intensive Care Unit; ROSC: return of spontaneous circulation; VF: ventricular fibrillation; VT: 
ventricular tachycardia. 
 
Table 2: Oxygen regimens tested in each study 
 
Study Timing of study treatment Conservative oxygen group Liberal oxygen group 
CLOSE 
Within 24 hours 





A target SpO2 of 88-92% w as 
applied until the patient w as 
discharged from ICU unless 
an FIO2 of >0.8 w as required, 
in w hich case, SpO2 targets 
w ere at the discretion of the 
treating clinician 
A target SpO2 of 96% a  
applied until the patient w as 
discharged from ICU 
COMACARE Follow ing ICU admission 
A target PaO2 from 75mmHg 
to 112.5mmHg for 36 h from 
the ICU admission or until the 
patient w as extubated or 
ventilation w as set to a 
spontaneous mode, w hichever 
occurred f irst 
A target PaO2 from 150mmHg 
to 187.5mmHg for 36 h from 
the ICU admission or until the 
patient w as extubated or 
ventilation w as set to a 
spontaneous mode, w hichever 




ROSC, w hen an 
advanced 
airw ay w as in 
place, and w hen 
Initially (Sept 2015 March 
2016) patients received 
2L/min; how ever, after April 
2016 initial administration of 
oxygen w as at 4L/min w ith a 
reduction to 2L/min the SpO2 
a  90% 
Oxygen w as delivered at >10 
L/min via a bag-valve 
reservoir until the patient w as 










the SpO2 w as 
96% 
HOT OR NOT 
Prehospital after 
sustained 
ROSC, w hen an 
advanced 
airw ay w as in 
place 
A target SpO2 of 90-94% w as 
applied for 72 hours or until 
the patient w as extubated, 
w hichever w as sooner 
In the pre-hospital period, the 
highest FIO2 possible w as 
used.  In hospital, the treating 
clinician could determine the 
SpO2 target but SpO2>95% 
w as suggested.  Protocol-
directed oxygen therapy 
continued for 72 hours or until 
the patient w as extubated, 
w hichever w as sooner 
ICU-ROX 
Within tw o hours 
of invasive 
mechanical 
ventilation in the 
ICU 
The upper limit monitored 
SpO2 alarm w as set to 
sound w hen the level w as 
>96%, and the FIO2 w as 
decreased to 0.21 if the 
SpO2 a  90%.  An 
alternative SpO2 limit could be 
used at the discretion of the 
treatment.  Patients received 
the assigned oxygen-therapy 
strategy until discharge from 
the ICU or 28 days after 
randomisation, w hichever w as 
earlier 
The use of an FIO2 <0.3 in 
patients w ho w ere invasively 
mechanically ventilated w as 
discourage.  Patients received 
the assigned oxygen-therapy 
strategy until discharge from 
the ICU or 28 days after 





follow ing ROSC 
FIO2 0.3 for 60 minutes; 
increased in 0.1 increments if  
the SpO2 a  <95% fo  5 
minutes 




follow ing ROSC 
A target SpO2 of 94-98% w as 
applied for 60 minutes FIO2 1.0 for 60 minutes 
 
 









Primary outcome – n/N (%) 
 odds ratio (95% CI); P value  
 adjusted for study* adjusted for all specified covariates† 








0.58 (0.35-0.96);  
P=0.04 
Secondary outcomes – n/N (%)    
Favourable 
neurological outcome 





































* Adjusted for study as a f ixed effect.  
 Adjusted for age, w hether or not the cardiac arrest was witnessed, whether or not there w as bystander CPR, 
w hether there was a shockable rhythm, the time until sustained return of circulation. 











Abbreviations: CI: Confidence Interval 
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